SCHEMBL311932

SCHEMBL311932

O=C(NCCc1ccccc1)N1CCCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.67
NPC1 O15118 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
HTT P42858 1/20 0.65
RAB9A P51151 1/20 0.65
EPHX2 P34913 2/20 0.63
TAAR1 Q96RJ0 1/20 0.60
TPSAB1 Q15661 1/20 0.59
TDP1 Q9NUW8 1/20 0.58
HRH3 Q9Y5N1 1/20 0.58
NAMPT P43490 2/20 0.57
EPHX1 P07099 1/20 0.56
DPP4 P27487 1/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
P2RX4 Q99571 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CA12 O43570 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210565 0.98 GAA (0.69) GAANPC1SMN1; SMN2HTTRAB9A
SCHEMBL10706721 0.90 NAMPT (0.71) GAANPC1RAB9AEPHX2TPSAB1
SCHEMBL17117343 0.89 NAMPT (0.69) GAANPC1SMN1; SMN2HTTRAB9A
SCHEMBL17117330 0.88 NAMPT (0.70) GAAEPHX2TPSAB1NAMPTEPHX1
Hydrochloric Acid SCHEMBL29789881 0.86 NAMPT (0.68) GAAEPHX2TPSAB1NAMPTEPHX1
SCHEMBL4974210 0.86 TPSAB1 (0.55) GAANPC1SMN1; SMN2HTTRAB9A
SCHEMBL5476364 0.86 KDM4E (0.71) GAASMN1; SMN2RAB9ATPSAB1NAMPT
SCHEMBL28218804 0.86 MEN1 (0.74) SMN1; SMN2TAAR1TPSAB1NAMPTMEN1
SCHEMBL17117320 0.84 DRD2 (0.65) GAANPC1SMN1; SMN2HTTRAB9A
SCHEMBL1575046 0.84 GAA (0.53) GAANPC1SMN1; SMN2HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3340981-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2018-07-04 EP disclosed
WO-2017035352-A1 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-02 WO disclosed
WO-2017035353-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-02 WO disclosed
US-8093246-B2 potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds LEXICON PHARMACEUTICALS, INC. (US) 2012-01-10 US disclosed
US-20080146571-A1 O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER OXFORD FINANCE LLC, AS COLLATERAL AGENT 2008-06-19 US disclosed
US-6790860-B2 USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. 2004-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146571-A1 O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER DPYD, DHFR, TYMP GAA 953/4885NPC1 1236/4885SMN1; SMN2 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.